BNP (B-type Natriuretic Peptide) vs GHK-Cu (Copper Peptide)
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
BNP (B-type Natriuretic Peptide)
BNP is a cardiac neurohormone released primarily by ventricles in response to volume/pressure overload. It's a major biomarker for heart failure and has therapeutic applications as nesiritide.
Full details →GHK-Cu (Copper Peptide)
GHK-Cu is a naturally occurring copper peptide found in human plasma, saliva, and urine. It plays important roles in wound healing, tissue repair, and has shown anti-aging properties in research.
Full details →Side-by-Side Comparison
| Aspect | BNP (B-type Natriuretic Peptide) | GHK-Cu (Copper Peptide) |
|---|---|---|
| Dose Range | 25 mcg–100 mcg | 1 mg–2 mg |
| Frequency | 1x daily | 1x daily |
| Cycle Length | 1–4 weeks | 4–8 weeks |
| Route | subcutaneous | subcutaneous |
| Mechanism | Similar to ANP - activates NPR-A receptors to produce vasodilation, natriuresis, and RAAS suppression. Released in response to ventricular wall stress. | Attracts immune cells and fibroblasts to wound sites, stimulates collagen and glycosaminoglycan synthesis, promotes angiogenesis, and has antioxidant effects. Modulates gene expression related to tissue repair. |
| Typical Dosage | Nesiritide (recombinant BNP): 2mcg/kg IV bolus followed by 0.01mcg/kg/min continuous infusion for acute decompensated heart failure. | Topical: Applied as serum or cream 1-2 times daily. Injectable: 1-2mg daily for research purposes. Microneedling protocols often use 0.5-1%. |
| Administration | Intravenous administration only. Used in acute care settings for heart failure. BNP levels also used diagnostically. | Most commonly used topically for skin applications. Can be injected subcutaneously for systemic effects. Often combined with microneedling for enhanced skin penetration. |
| Side Effects | Hypotension (common and dose-limiting), headache, nausea, and potential renal function worsening in some patients. | Topical use is generally well-tolerated. May cause temporary skin irritation or redness in sensitive individuals. Injectable use may cause injection site reactions. |
| Best For |
What They Have in Common
BNP (B-type Natriuretic Peptide), GHK-Cu (Copper Peptide) are both commonly used for:
Which Has Stronger Evidence?
- Recovery & Healing: GHK-Cu (Copper Peptide) has stronger research support.
| Goal | BNP (B-type Natriuretic Peptide) | GHK-Cu (Copper Peptide) |
|---|---|---|
| Recovery & Healing | medium | high |
Key Studies
BNP (B-type Natriuretic Peptide)
- Developing a risk score for B-type natriuretic peptide (BNP) ≥ 100 pg/ml levels: the suita study.
BMC cardiovascular disorders, 2025
- Inhibition of Fap Promotes Cardiac Repair by Stabilizing BNP.
Circulation research, 2023
- Body Composition Measures and N-terminal pro-B-type Natriuretic Peptide (NT-pro-BNP) in US Adults.
Clinical chemistry, 2023
GHK-Cu (Copper Peptide)
- Middle-aged mice treated with GHK-Cu peptide administered intraperitoneally or intranasally show behavioral rescue but divergent hippocampal aging programs.
Research square, 2026
- Glycyl-L-histidyl-L-lysine-Cu2(+) (GHK-Cu) Attenuates CuSO(4) or LPS induced-inflammation in Zebrafish larvae model.
European journal of pharmacology, 2026
- The Regenerative Potential of GHK-Cu in Aesthetic Medicine.
Aesthetic surgery journal, 2026
Ready to Learn More?
Looking for trusted sources?